Palisade Bio, Inc. (PALI)
After hours:
| Previous close | 6.46 |
| Open | 6.42 |
| Bid | 4.58 x 200 |
| Ask | 7.82 x 200 |
| Day's range | 5.94 - 6.44 |
| 52-week range | 3.82 - 36.60 |
| Volume | |
| Avg. volume | 1,119,347 |
| Market cap | 5.963M |
| Beta (5Y monthly) | 1.35 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Palisade Bio Reports First Quarter 2024 Financial Results and Provides Business Update
– Company on track to commence Phase 1 human clinical study of lead product candidate, PALI-2108, for the treatment of Ulcerative Colitis (UC) before year end – Sufficient cash on hand to execute on business plan and reach clinical and regulatory milestones into 2025 Carlsbad, CA, May 14, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio” or the “Company”), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living w
- GlobeNewswire
Palisade Bio Appoints Margery Fischbein to its Board of Directors
Palisade Bio, Inc. Margery Fischbein Wall Street and biotech industry veteran with expertise across corporate finance, business development, M&A, licensing, and strategic alliance transactions, globally Carlsbad, CA, May 07, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio” or the “Company”), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announ
- GlobeNewswire
Palisade Bio Announces Closing of $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules
Carlsbad, CA, May 07, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, is announcing today that it has closed its previously announced private placement with an institutional investor for the purchase of 615,242 shares of common stock (or certain pre-funded warrants in lieu thereof) for gross proceeds of approximately $4 million,
